CYBN

Cybin (CYBN)

Cybin Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NEO:CYBN

日付	受信時刻	ニュースソース	見出し	コード	企業名
2022/03/24	21 : 18	InvestorsHub NewsWire	Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants	NEO:CYBN	Cybin Inc
2022/03/16	22 : 40	InvestorsHub NewsWire	Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022	NEO:CYBN	Cybin Inc
2022/02/18	22 : 37	InvestorsHub NewsWire	Cybin Announces Additional Adelia Milestone Achievement	NEO:CYBN	Cybin Inc
2022/02/15	22 : 29	InvestorsHub NewsWire	The Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental Health	NEO:CYBN	Cybin Inc
2022/02/09	22 : 36	InvestorsHub NewsWire	Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders	NEO:CYBN	Cybin Inc
2022/01/27	22 : 35	InvestorsHub NewsWire	Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022	NEO:CYBN	Cybin Inc
2022/01/12	00 : 08	InvestorsHub NewsWire	Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain	NEO:CYBN	Cybin Inc
2021/12/22	22 : 21	InvestorsHub NewsWire	Cybin Provides 2021 Year End Summary	NEO:CYBN	Cybin Inc
2021/12/21	22 : 57	InvestorsHub NewsWire	Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference	NEO:CYBN	Cybin Inc
2021/12/15	23 : 44	InvestorsHub NewsWire	Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders	NEO:CYBN	Cybin Inc
2021/12/09	01 : 11	InvestorsHub NewsWire	Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder	NEO:CYBN	Cybin Inc
2021/12/01	00 : 07	InvestorsHub NewsWire	Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress	NEO:CYBN	Cybin Inc
2021/11/15	22 : 31	InvestorsHub NewsWire	Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights	NEO:CYBN	Cybin Inc
2021/11/08	22 : 29	InvestorsHub NewsWire	Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health	NEO:CYBN	Cybin Inc
2021/11/04	20 : 46	InvestorsHub NewsWire	Cybin Granted DEA Schedule I Manufacturing License	NEO:CYBN	Cybin Inc
2021/11/02	22 : 13	InvestorsHub NewsWire	Cybin Hosting Research and Development Briefing on November 8, 2021	NEO:CYBN	Cybin Inc
2021/10/26	22 : 44	InvestorsHub NewsWire	Cybin Announces FDA Investigational New Drug Authorization of Cybin's Sponsored Feasibility Study Using Kernel Flow Technology	NEO:CYBN	Cybin Inc
2021/10/12	22 : 23	InvestorsHub NewsWire	Cybin Files an International Patent Application Covering Psychedelic Delivery Methods	NEO:CYBN	Cybin Inc
2021/08/19	23 : 34	InvestorsHub NewsWire	Cybin Files Two Additional International Patent Applications in Support of the Company's Research Phase Programs	NEO:CYBN	Cybin Inc
2021/08/04	23 : 00	InvestorsHub NewsWire	Cybin to Commence Trading on the NYSE American on August 5	NEO:CYBN	Cybin Inc
2021/07/22	22 : 41	InvestorsHub NewsWire	Cybin Announces Conditional Listing Approval from NYSE American	NEO:CYBN	Cybin Inc
2021/07/13	21 : 23	InvestorsHub NewsWire	Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy	NEO:CYBN	Cybin Inc
2021/07/06	20 : 21	InvestorsHub NewsWire	Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence	NEO:CYBN	Cybin Inc
2021/06/24	22 : 42	InvestorsHub NewsWire	Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board	NEO:CYBN	Cybin Inc
2021/06/22	22 : 39	InvestorsHub NewsWire	Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study	NEO:CYBN	Cybin Inc
2021/06/16	23 : 44	InvestorsHub NewsWire	Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004	NEO:CYBN	Cybin Inc
2021/06/08	20 : 16	InvestorsHub NewsWire	Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and	NEO:CYBN	Cybin Inc